S

Secretome Therapeutics

Secretome Therapeutics is focused on developing regenerative cardiac therapies, particularly targeting conditions like Duchenne muscular dystrophy associated cardiomyopathy. The company aims to restore and regenerate cardiac function through innovative cellular therapies, with recent funding set to advance their clinical trials and manufacturing capabilities.

Total raised
$30M
tracked to date
Latest round
Series A
May 28, 2026
Known investors
1
led by RA Capital Management

Is this your company?

Claim this profile to get matched with investors who fund Health startups in United States.

Claim this profile →

🏆 Featured in Datapile’s Q2 2026 USA Funding Report

Read the Q2 2026 USA report →
Add this badge to your site
<a href="https://datapile.co/reports/q2-2026-usa-startup-funding" target="_blank" rel="noopener" style="display:inline-flex;align-items:center;gap:8px;padding:9px 16px;border-radius:9999px;background:#0B1224;color:#ffffff;font:600 13px/1.2 -apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Arial,sans-serif;text-decoration:none;border:1px solid #7C5CFF"><span style="display:inline-block;width:11px;height:11px;border-radius:3px;background:#7C5CFF"></span>Featured in Datapile&rsquo;s Q2 2026 USA Funding Report</a>

Funding history

  1. 1
    $30MSeries AMay 28, 2026

    Led by RA Capital Management

    Announcement ↗

Investors in Secretome Therapeutics

Backers from this company's tracked funding rounds.

  • RRA Capital ManagementLead investorVC firm

Secretome Therapeutics in the news

Coverage of this company's funding, tracked by Datapile.

More Health companies

Recently funded startups in the same category.

Related on Datapile